Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease: Efficacy of an herbal compound in decreasing steatosis and transaminase activities in non-alcoholic fatty liver disease

• Autor(a) principal: Abbas Zojaji, Seyyed
• Data de Publicação: 2022
• Outros Autores: Mosannen Mozaffari, Hooman, Ghaderi, Pouya, Zojaji, Faegheh, Hadjzadeh, Mousa-Al-Reza, Seyfimoqadam, Monireh, Ghorbani, Ahmad
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/206126
• topic: Anethum graveolens; Citrus; Cynara scolymus; Fatty liver; Portulaca oleracea; Silybum marianum

Hepatoprotective effects of many herbal agents have been reported in animal studies and clinical trials. In this study, five hepatoprotective plants with potent antioxidant, anti-inflammatory, and hypolipidemic effects were chosen to prepare a polyherbal compound for managing NAFLD. Sixty patients with NAFLD were randomly divided into treatment and control groups (2:1 ratio). Both group were advised to take healthy diet and exercise. The treatment group also received herbal capsules containing 400 mg of the mixture of Anethum graveolens, Citrus aurantium, Cynara scolymus, Portulaca oleracea, and Silybum marianum (2 capsules, thrice daily, for two months). The liver ultrasound and biochemical markers including the serum lipids, liver enzymes, and glucose were evaluated before starting the study and at the end of the treatment. Thirty patients in the treatment group and sixteen patients in the control group completed the study. The herbal compound significantly decreased the serum level of alanine transaminase (ALT), aspartate transaminase (AST), and total cholesterol. Treatment with the herbal compound significantly improved the grade of the fatty liver, but no significant change was found in the control group. In conclusion, the formulated herbal compound appeared to be effective in biochemical improvement and decreasing the grade of the fatty liver in the patients with NAFLD.